ChloroquineV1, Main, Exploration, bibRecord, 001015

Management of lymphangioleiomyomatosis.

Identifieur interne : 001015 ( Main/Exploration ); précédent : 001014; suivant : 001016

Management of lymphangioleiomyomatosis.

Auteurs : Angelo M. Taveira-Dasilva [États-Unis] ; Joel Moss [États-Unis]

Source :

F1000prime reports [ 2051-7599 ] ; 2014.

RBID : pubmed:25580270

Abstract

Lymphangioleiomyomatosis (LAM), a multisystem disease affecting almost exclusively women, is characterized by cystic lung destruction and presents with dyspnea, recurrent pneumothoraxes, chylous effusions, lymphangioleiomyomas, and angiomyolipomas. It is caused by the proliferation of a cancer-like LAM cell that possesses a mutation in either the tuberous sclerosis complex (TSC)1 or TSC2 genes. This article reviews current therapies and new potential treatments that are currently undergoing investigation. The major development in the treatment of LAM is the discovery of two mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, as effective drugs. However, inhibition of mTOR increases autophagy, which may lead to enhanced LAM cell survival. Use of autophagy inhibitors, for example, hydroxychloroquine, in combination with sirolimus is now the subject of an ongoing drug trial (SAIL trial). Another consequence of mTOR inhibition by sirolimus is an increase in Rho activity, resulting in reduced programmed cell death. From these data, the concept evolved that a combination of sirolimus with disruption of Rho activity with statins (e.g. simvastatin) may increase TSC-null cell death and reduce LAM cell survival. A combined trial of sirolimus with simvastatin is under investigation (SOS trial). Since LAM occurs primarily in women and TSC-null cell survival and tumor growth is promoted by estrogens, the inhibition of aromatase to block estrogen synthesis is currently undergoing study (TRAIL trial). Other targets, for example, estrogen receptors, mitogen-activated protein kinase inhibitors, vascular endothelial growth factor-D signaling pathway, and Src kinase, are also being studied in experimental model systems. As in the case of cancer, combination therapy may become the treatment of choice for LAM.

DOI: 10.12703/P6-116
PubMed: 25580270

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of lymphangioleiomyomatosis.</title>
<author><name sortKey="Taveira Dasilva, Angelo M" sort="Taveira Dasilva, Angelo M" uniqKey="Taveira Dasilva A" first="Angelo M" last="Taveira-Dasilva">Angelo M. Taveira-Dasilva</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda, Maryland 20892-1590 USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda, Maryland 20892-1590 USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:25580270</idno>
<idno type="pmid">25580270</idno>
<idno type="doi">10.12703/P6-116</idno>
<idno type="wicri:Area/PubMed/Corpus">000271</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000271</idno>
<idno type="wicri:Area/PubMed/Curation">000271</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000271</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000284</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000284</idno>
<idno type="wicri:Area/Ncbi/Merge">000273</idno>
<idno type="wicri:Area/Ncbi/Curation">000273</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000273</idno>
<idno type="wicri:doubleKey">2051-7599:2014:Taveira Dasilva A:management:of:lymphangioleiomyomatosis</idno>
<idno type="wicri:Area/Main/Merge">001016</idno>
<idno type="wicri:Area/Main/Curation">001015</idno>
<idno type="wicri:Area/Main/Exploration">001015</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Management of lymphangioleiomyomatosis.</title>
<author><name sortKey="Taveira Dasilva, Angelo M" sort="Taveira Dasilva, Angelo M" uniqKey="Taveira Dasilva A" first="Angelo M" last="Taveira-Dasilva">Angelo M. Taveira-Dasilva</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda, Maryland 20892-1590 USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda, Maryland 20892-1590 USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Cardiovascular and Pulmonary Branch, NHLBI NIH Building 10, Room 6D03, MSC 1590, Bethesda</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">F1000prime reports</title>
<idno type="ISSN">2051-7599</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lymphangioleiomyomatosis (LAM), a multisystem disease affecting almost exclusively women, is characterized by cystic lung destruction and presents with dyspnea, recurrent pneumothoraxes, chylous effusions, lymphangioleiomyomas, and angiomyolipomas. It is caused by the proliferation of a cancer-like LAM cell that possesses a mutation in either the tuberous sclerosis complex (TSC)1 or TSC2 genes. This article reviews current therapies and new potential treatments that are currently undergoing investigation. The major development in the treatment of LAM is the discovery of two mammalian target of rapamycin (mTOR) inhibitors, sirolimus and everolimus, as effective drugs. However, inhibition of mTOR increases autophagy, which may lead to enhanced LAM cell survival. Use of autophagy inhibitors, for example, hydroxychloroquine, in combination with sirolimus is now the subject of an ongoing drug trial (SAIL trial). Another consequence of mTOR inhibition by sirolimus is an increase in Rho activity, resulting in reduced programmed cell death. From these data, the concept evolved that a combination of sirolimus with disruption of Rho activity with statins (e.g. simvastatin) may increase TSC-null cell death and reduce LAM cell survival. A combined trial of sirolimus with simvastatin is under investigation (SOS trial). Since LAM occurs primarily in women and TSC-null cell survival and tumor growth is promoted by estrogens, the inhibition of aromatase to block estrogen synthesis is currently undergoing study (TRAIL trial). Other targets, for example, estrogen receptors, mitogen-activated protein kinase inhibitors, vascular endothelial growth factor-D signaling pathway, and Src kinase, are also being studied in experimental model systems. As in the case of cancer, combination therapy may become the treatment of choice for LAM. </div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Maryland"><name sortKey="Taveira Dasilva, Angelo M" sort="Taveira Dasilva, Angelo M" uniqKey="Taveira Dasilva A" first="Angelo M" last="Taveira-Dasilva">Angelo M. Taveira-Dasilva</name>
</region>
<name sortKey="Moss, Joel" sort="Moss, Joel" uniqKey="Moss J" first="Joel" last="Moss">Joel Moss</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001015 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001015 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25580270
   |texte=   Management of lymphangioleiomyomatosis.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25580270" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Management of lymphangioleiomyomatosis.

Management of lymphangioleiomyomatosis.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.